Propranolol 18F-FDG PET/CT: A Noninvasive Approach for Differential Diagnosis of Hibernoma and Liposarcoma - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Clinical Nuclear Medicine Année : 2017

Propranolol 18F-FDG PET/CT: A Noninvasive Approach for Differential Diagnosis of Hibernoma and Liposarcoma

Résumé

A 76-year-old woman was referred for F-FDG PET/CT assessment of a colorectal cancer. A 9-cm F-FDG-avid fatty mass was depicted in the right thigh, suggesting either hibernoma or liposarcoma. Because MRI could not rule out well-differentiated liposarcoma, and biopsy was difficult, surveillance was decided. Follow-up PET/CT showed an increase of F-FDG uptake in the fatty mass. We repeated PET/CT after oral administration of 60 mg of propranolol 1 hour before F-FDG injection. A dramatic decrease in F-FDG uptake was observed, strongly supporting the diagnosis of hibernoma.

Domaines

Cancer
Fichier non déposé

Dates et versions

inserm-02093131 , version 1 (08-04-2019)

Identifiants

Citer

Renaud Ciappuccini, Stéphane Bardet, Nicolas Aide. Propranolol 18F-FDG PET/CT: A Noninvasive Approach for Differential Diagnosis of Hibernoma and Liposarcoma. Clinical Nuclear Medicine, 2017, 42 (11), pp.879-880. ⟨10.1097/RLU.0000000000001830⟩. ⟨inserm-02093131⟩
36 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More